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Abstract 
Purpose: To develop and optimize carvedilol transdermal delivery system. 
Methods: Solvent casting method was used to prepare patches using polymethyl methacrylate (PMMA) 
and Eudragit E100 (EE100) polymers, dimethylsulfoxide (DMSO) penetration enhancer, dibutylphthalate 
(DBP) plasticizer and Tween 80 surfactant. A 23 factorial design was used based on three variables 
(PMMA, EE100, DMSO).  at two levels Second order polynomial equations indicating interplay of 
ingredients were obtained by factorial design using SigmaTech software for 1, 4, 8 and 20 h release 
data.  so the design was extended to central composite design (CCD). The target formulation was 
obtained from contour plots and evaluated for various physicochemical parameters. including in-vitro 
dissolution studies.  
Results: Curvature effect was observed in F1 to F8 formulations, highlighting the interplay of 
ingredients. The interaction term  (X2X3)exhibited highest Sum of Squares SS ratio at 1, 4, and 8 h data 
with positive coefficients indicating interaction; and so extended to CCD.  From contour plots target 
formulation, F19, was identified and evaluated. The release data, were subjected to kinetic analysis, 
which followed Higuchi (diffusion) model (R2 = 0.9886). 
Conclusion: F19 yielded release profile nearer to the theoretical predictions with R2 of 0.9888 and 
followed Higuchi kinetics. Thus, a diffusion-mediated carvedilol matrix patch was successfully 
developed. 
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Continuous intravenous infusion is recognized as 
a superior mode of drug delivery not only to 
bypass first-pass elimination, but also to maintain 
a constant, prolonged, and therapeutically-
effective drug level in the body. Such mode of 
drug delivery necessitates hospitalization of 
patients and close medical supervision of the 
medication. There has been an increasing 
awareness that the benefits of intravenous drug 
infusion can be closely duplicated (without its 
potential hazards) by transdermal administration 
[1]. Several transdermal drug delivery systems 
(TDDS) aiming to achieve systemic delivery have 
recently been developed.   
 
Few drugs are already available as transdermal 
patches in the market for the treatment of angina, 
hypertension, menopausal syndrome, hypogo-
nadism, motion induced nausea etc [2]. 
Carvedilol, a non selective β- adrenergic blocker 
with α1 blocking activity, is one of the most widely  
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Level of PMMA, 
X1 (mg) 
Level of Eudragit 
E 100, X2 (mg) 
Level of DMSO, 
X3 (mg) 
F1 1 -1 (200) -1 (40) -1 (60) 
F2 X1 +1 (300) -1 (40) -1 (60) 
F3 X2 -1 (200) +1 (120) -1 (60) 
F4 X1X2 +1 (300) +1 (120) -1 (60) 
F5 X3 -1 (200) -1 (40) +1 (100) 
F6 X1X3 +1 (300) -1 (40) +1 (100) 
F7 X2X3 -1 (200) +1 (120) +1 (100) 
F8 X1X2X3 +1 (300) +1 (120) +1 (100) 
F9-F12 Midpoint 0 (250) 0 (80) 0 (80) 
F13 +2X1 +2 (350) 0 (80) 0 (80) 
F14 -2X1 -2 (150) 0 (80) 0 (80) 
F15 +2X2 0 (250) +2 (160) 0 (80) 
F16 -2X2 0 (250) -2 (0) 0 (80) 
F17 +2X3 0 (250) 0 (80) +2 (120) 
F18 -2X3 0 (250) 0 (80) -2 (40) 
Key: Formulations F1 - F 8 are factorial design, 23; formulations F9 - F12 (midpoints) are for statistical analysis; formulations 
F13 - F18 are star points of central composite design; Other ingredients are: dibutyl phthalate (80 mg), Tween 80 (16 mg) and  
carvedilol (80 mg). 
 
prescribed drugs in the management of 
hypertension [3]. Low oral bioavailability (25 %) 
due to extensive first pass metabolism, a short 
plasma half-life (6 h) and the long term usage 
made carvedilol an ideal drug for transdermal 
route of administration [3-5]. Furthermore, the 
low molecular weight (406.5), log P (4.19), log 
pKa (7.9), low dose 25-50 mg and low melting 
point 114 °C confers on the drug ability for it to 
be easily absorbed through the skin.  
 
Polymers selected include polymethyl 
methacrylate, for its rate controlling attribute and 
Eudragit E100 for its swelling [6]. Reports are 
available on the use of polymethyl methacrylate 
and Eudragit E100 for the preparation of 
transdermal (TD) patches individually, but not in 
a combination till date [7,8].  
 
The aim of the present study was to develop and 
optimize a suitable TDDS of carvedilol using 2 x 






Carvedilol was a gift from Aurobindo 
Pharmaceuticals, Hyderabad. Eudragit E100 was 
a gift from Strides Arco Labs Pvt Limited, 
Bangalore. Polymethylmethacrylate (PMMA) was 
purchased from Himedia laboratories, Mumbai, 
India. All the other chemicals were obtained from 
SD Fine Chemicals. 
 
Drug/excipient compatibility studies 
 
To ascertain the compatibility between carvedilol 
and excipients, differential scanning calorimetry 
DSC studies were carried out on carvedilol, 
PMMA, EE100 and a physical mixture of these 
three components (1:1:1) using a dynamic DSC 
(Shimadzu DSC-50 Thermal Analyzer) in 
nitrogen atmosphere at the heating rate of 5 
°C/min. Fourier transform – infrared (FT-IR) 
studies (Shimadzu, Japan) were also carried out 
on carvedilol, PMMA, EE100 and their physical 
mixture.  
 
Preparation of TDDS 
 
Transdermal patches were prepared by casting 
method on a petriplate by solvent evaporation 
[9]. All the ingredients were dissolved in 
chloroform individually, mixed with the polymers 
dispersion and poured in petriplates. Then the 
plasticizer, surfactant and penetration enhancer 
were added and mixed. Prepared polymeric 
dispersion was poured on a petriplate of 71 cm2 
area and was covered with inverted funnel (to 
control evaporation of solvent and avoiding 
cracking and breaking of patch) and allowed to 
dry overnight. The dried patches were removed 
and stored in a dessicator. Concentrations of 
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PMMA, EE100 and DMSO were varied as per 
the design, and patches were observed for 
flexibility and other properties.  
 
Formulation design of carvedilol TDDS  
 
Preliminary investigation based on trial and error, 
experiments yielded an empirical formulation. 
Design of experiments (DOE) was attempted 
using 23 factorial design [10]. Three variables at 
two levels and with actual values were 
represented in Table I. The levels of all other 
ingredients in the formulation were fixed and the 
basic plan was identified. Other ingredients 
(fixed) were; carvedilol (80 mg), dibutylphthalate 
(80 mg), Tween-80 (16 mg) and chloroform (15 
ml). Midpoints (code 0) were also considered, so 
that errors can be estimated and statistical 
analysis was attempted and the analysis yielded 
a curvature effect.  Thus, a composite design 
with additional 6 formulations was conducted.  
 
Central composite design 
 
As per the principles of central composite design, 
six formulations were added, by extending to five 
levels (-2, -1, 0, +1 and +2) [11]. The variables 
and levels along with detailed design with actual 
values are reported in Table I.  
 
Evaluation of transdermal patches 
 
The transdermal patches were evaluated for the 
following physicochemical parameters [12, 13]. 
 
Thickness 
The thickness of the transdermal patches was 
measured using a screw gauge at different points 




Ten patches of 1 cm2 were weighed using digital 
balance (Schimadzu, Japan) and the average 
weight was calculated. 
 
Folding endurance 
Folding endurance was determined by folding 
and opening the patch at the same place 
repeatedly until it breaks. The result was 
expressed as a number. 
 
Moisture content determination 
Patches (n = 10) were weighed individually and 
kept in a dessicator (calcium chloride) at room 
temperature for 24 h and the weight at various 
intervals during the period was noted, until there 
was no further loss in weight. The moisture 
content was calculated as % weight loss. 
 
Moisture uptake test 
The films (n = 3) were weighed accurately and 
placed in a dessicator of 75 %RH maintained 
using saturated solution of sodium chloride. After 
three days, the films were weighed and the 
moisture uptake was calculated as the % 
difference between the final and initial weights 
with respect to initial weight. 
 
Drug content determination 
Transdermal patches were cut into pieces of 1 x 
1 cm2 and carvedilol content was determined (n = 
3). A patch of 1 cm2 was taken into a 50 ml 
beaker and 10 ml of methanol was added and 
shaken for 5 min. One ml was taken and diluted  
to 5 ml with phosphate buffer (pH 7.4) and 
carvedilol content determined spectrophoto-
metrically at 285 nm in the concentration range 
of 5 - 30 µg/ml.  
 
In vitro release studies  
Carvedilol release from the transdermal system 
was evaluated using the USP paddle over disc 
dissolution apparatus prescribed for TDDS [14, 
15a]. The dissolution test apparatus was 
thermostated at 32 ± 0.5 °C and stirred at 50 
rpm. The film was fixed on inverted glass 
petriplate using cyanoacrylate adhesive allowing 
drug to release only from upper surface and was 
placed at the bottom of the vessel containing 500 
ml of phosphate buffer, pH 7.4. Aliquots of 5 ml 
of sample were withdrawn at every half an hour 
up to 2 h, and thereafter periodically upto 24 h, 
replacing with equal volume of buffer. The 
samples were analyzed spectrophotometrically at 
285 nm. Cumulative carvedilol released was 
calculated. Triplicate determinations were carried 
out. 
 
Data analysis  
The analysis of factorial design and central 
composite design was attempted using 
Sigmatech software (Swarooptech, Hyderabad, 
India). The software has built in statistical 
analysis, standard error of the estimate, error of 
variance, standard deviation, F distribution test, 
and orthogonal functions evaluation. The 
analysis output gave a print out of a table 
containing sum of squares and coefficients. A 
second order equation was written from the 
coefficients. Further contour plots were 





Physical properties of carvedilol TDDS 
 
The texture and tackiness of the patches were 
satisfactory. The thickness of the patches ranged 
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from 33 to 50 μm and varied with the 
composition of patches. The average weight of 
films of 1 cm2 ranged from 60 – 87 mg and was 
proportional to the dry weight of the ingredients. 
Folding endurance varied from 32 - 70, and 
inversely proportional to PMMA concentration. 
Moisture content and uptake were related to the 
concentration of EE100 to a large extent. 
Carvedilol drug loading varied from 95 to 98 %. 
 
In vitro drug release  
 




Figure 1: In vitro carvedilol release profile from 
different TDDS systems. Key: X = Fmid;    = F14; ∆ = 
Ftarget; o = F7 
 
The concentrations of EE100 and DMSO were 
highest while that of PMMA was  lowest for F7 
and so reported higher release of 95%. The 
release of carvedilol at the midpoints (62%) was 
repeated four times (F9 – F12) for the purpose of 
statistical evaluation. F14 has shown a release of 
73%. The carvedilol release in F19 (Target) 
(88%) was achieved nearest to the predicted 
value (24 h), and is presented in Fig 1 (Ftarget). 
The dissolution data of 24 h was suitably divided 
into four parts 1, 4, 8 and 24 h and analysis was 
attempted with the polynomial equations 
obtained given in the Table 2. This approach was 
similar to oral controlled drug delivery of 
metoprolol succinate of USP [15b]. Though the 
present formulation was TDDS, this analysis 
adopted the same time frame. 
 
Cumulative carvedilol release was abstracted 
from all 12 formulations and the responses were 
analyzed as per the factorial design using 
SigmaTech software. The central composite 
design was planned by including two more 
levels, +2 and -2 for all the three variables [11]. 
Thus six more formulations were developed 
(Table I, F13 to F18) formulated and evaluated 
for physical parameters and for in vitro carvedilol 
release (F13 to F18). 
 
Central composite design - contour plot 
analysis 
 
For all 18 formulations, carvedilol release data 
were compiled and analyzed for 1, 4, 8 and 20 h 
time points through contour plots [11]. Since the 
central composite design had three variables, it 
was necessary to keep one variable as constant 
and correlate other two variables. After extensive 
analysis of contour plots, it was decided to keep 
X3 (DMSO) at 80 mg, and X1 (PMMA) and X2 
(EE100) plots were analyzed. For finalizing the 
composition, formulationcriteria (in vitro 
carvedilol release) was fixed as follows: 1 h-23%, 
4 h - 30-40%, 8 h - 55-60% and 20 h -80%.  For 
1 h data analysis, contour plot (X1 vs X2) was 
recorded in Fig 2a. For the given criteria, 
polymers were identified as  (150 mg (PMMA), 
40 mg (Eudragit E100) of X1  (PMMA) and X2 
(Eudragit E100) (Fig 2a). From 4 h data, contour 
 














y=23.4905 - 0.4177X1 + 0.09X2 + 0.1722X1X2 







y=31.6375-0.9485X1 + 1.6125X2 - 1.6345X1X2 
+ 1.2992X3 - 1.0777X1X3 + 2.8003X2X3 - 






y=48.2442 - 4.3632X1+1.7823X2 - 3.5422X1X2 







y= 59.9973 – 6.6635X1 + 3.255X2 - 
5.6662X1X2 + 4.0088X3 – 1.581X1X3 + 






* Curvature effect (non-linear effect) was obtained from the software, ay 95 % confidence level. If the curvature values are 
positive as well as negative (based on F1 to F12), then the curvature effect was predominant. Due to curvature effect, a 
minimum of three levels for each variable is necessary and experimentation was essential. Thus, second order equations were 
obtained, which are presented as contour plots. 
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Theoretical,   
(% Cumulative carvedilol release from 
contour plot) 
Experimental,  
(% Cumulative  carvedilol 
release) 
Error (%) 
1.0 24 21.503 ± 0.360 10.404 
4.0 32 38.476 ± 0.573 -20.237 
8.0 55 59.229 ± 0.458 -7.27 




(a)        (b) 
Figure 2: X1 vs X2 contour plot from central composite design. (a) 1 h release and (b) 8 h release. X3 (DMSO) 
was constant. Target formulation, PMMA-150 mg (code -2), Eudragit E100 – 40 mg (code -1) and DMSO – 80 
mg (code -0). 
 
plot (X1 Vs X2) indicated the point (150 mg 
(PMMA), 40 mg (Eudragit E100). These 
conclusions were agreeing with 1 h data 
analysis. For 8 h data analysis, contour plot (X1 
Vs X2) was recorded in Fig 2b. The plots are 
peak and mounds. The optimal point must be at 
the top or round. A small change in the variables 
produced a drastic change in the response. In 
such a case, the optimized parameters must be 
critical. For the expected release of carvedilol, 
the point  (-2, -2) i.e., 150 mg PMMA and 40 mg 
of  Eudragit E100 respectively, were selected. X1 
and X2 are codes and -2 and -1 are levels of X1 
and X2 respectively. Equations contained codes. 
These can be levels such as -2, -1, 0, +1, +2 
etc., of X1 and X2 (Fig 2b) were selected. For 20 
h data, contour plot (X1 Vs X2) indicated 
curvilinear or nearly straight line. For the 
expected release of carvedilol (80 to 90%), point  
 (150 mg (PMMA), 40 mg (Eudragit E100) was 
chosen Any desired level can be an input for 
obtaining the desired response (dissolution). 
After obtaining the codes for target, these were 




The swelling and permeability of EE100 and 
penetration enhancer might be responsible for 
the release of carvedilol. The release of 
carvedilol was almost uniform in the initial 30 min 
in all the formulations, approximately 20% 
release and no burst effect observed. Evaluation 
of release pattern was suitably divided on hourly 
basis and was evaluated as following. 
 
The first hour release data was analyzed and 
represented as a polynomial equation. The 
contribution of variables independently has no 
influence on the carvedilol release. The 
interaction of X2X3was highest with SS ratio (37.3 
%) and a positive sign of the coefficient (0.7478). 
It indicated that the higher the amount of X2 and 
X3, the greater the carvedilol release. This was 
reasonable, because EE100 control the release 
and DMSO promote the carvedilol release. 
Interaction terms (%SS ratio  X1X2, X2X3, X1X3  
and X1X2X3) contributed approximately 88 % and 
thus curvature effect was found significant. 
 
The fourth hour release data was analyzed and 
represented in polynomial equation 2 (Table II). 
The interaction term X2X3 was the highest SS 
ratio (46.479 %) with a positive sign of the 
coefficient (2.8003) indicated direct relation 
between components and carvedilol release. 
The contribution of interaction terms was 
approximately 70%. Finally, it was concluded 
that curvature effect was predominant. The 
results were nearly same as that of 1 h analysis. 
 
The eight hour release data was analyzed and 
represented as a polynomial equation. The 
interaction term of X2X3 was the highest with SS 
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ratio (20.63 %) with positive sign of the 
coefficient (4.2238). The contribution of 
interaction terms was to the tune of 57 % and 
curvature effect was predominant. The results 
were nearly same as that of 1 h and 4 h data 
analysis.  
 
The 20 h release data was analyzed and also 
represented as a polynomial equation. PMMA 
(X1) had the highest SS ratio (35.80%) with a 
coefficient of negative sign (-6.6635), because 
PMMA was the release retardant. The 
contribution of interaction terms was 
approximately 44%. Finally it was concluded that 
curvature effect was moderate and hence 
factorial design is inadequate. The time phased 
analysis indicated consistently curvature effect. 
Hence, factorial design was not sufficient and so 
central composite design was attempted for 
obtaining the target formulation. 
 
Evaluation of the physical characteristics of the 
patches were satisfactory. In vitro carvedilol 
release of F14 was nearest to the expected 24 h 
release with PMMA content was at the lowest (-2 
level) in F14. 
 
Contour plots permitted the composition PMMA 
as 150 mg (-2), EE100 as 40 mg (-1) and DMSO 
as 80 mg; all the other ingredients in the 
formulation remained the same. Then 
transdermal patches were casted successfully 
and observed for thickness, weight, folding 
endurance, moisture content and moisture 
uptake and were found satisfactory. Carvedilol 
content was found to be 98.61%. A transdermal 
patch of size 3.80 cm2 containing 4.14 mg 
carvedilol was utilized for in vitro carvedilol 
release studies and the data of F19 was reported 
in Fig. 1. The release of carvedilol was 20% in 
the initial 30 min and was considered to be 
necessary, so as to improve the initial carvedilol 
absorption through skin. Then, the release must 
be linear, so as to maintain the levels of 
carvedilol. The theoretical and observed release 
of carvedilol target patch was reported in Table 3 
together with the error.  
 
Thus the target formulation (F19) showed 
predicted carvedilol release which fitted first 
order release kinetics. However, the release 
profile of the prepared patches followed Higuchi’s 
equation indicating that permeation of drug from 
the patches was governed by diffusion 
mechanism. As many release processes can be 
represented by a coupling of Fickian and non-
Fickian mechanism. Ritger and Peppas 
introduced the power law equation Mt/M∞ =Ktn to 
characterize the controlled release behavior of a 
drug from polymer matrices [16]. The n value (n 
= 0.4376) obtained on the present study 
indicates that the amount of drug released by 
Fickian diffusion predominated. So it can be 





A matrix type TDDS of carvedilol was 
successfully developed using casting method. 
PMMA and EE100 were compatible with 
carvedilol. The factorial design (12 formulations) 
exhibited curvature effect. The transdermal 
patches exhibited good physical properties as 
well as suitable release. Second order equations  
representedcontour plots and were analyzed for 
obtaining the target formulation. The target 
formulation gave satisfactory in vitro carvedilol 
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